抑癌蛋白 M 人

Oncostatin M (OSM) is produced by activated T cells, monocytes and Kaposi′s sarcoma cells. OSM shares several structural and functional characteristics with leukemia inhibitory factor (LIF), interleukin-6 (IL-6), and ciliary neurotrophic factor (CNTF).

Human oncostatin-M has been used to stimulate bovine full-depth cartilage explants. It has also been used to culture embryonic stem cells in standard minimum essential medium-α.

Oncostatin M (OSM) is a growth and differentiation factor that participates in the regulation of neurogenesis, osteogenesis and hematopoiesis. It can exert both stimulatory and inhibitory effects on cell proliferation. OSM stimulates the proliferation of fibroblasts, smooth muscle cells and Kaposi′s sarcoma cells, but, inhibits the growth of some normal and tumor cell lines. It also promotes cytokine release [e.g. interleukin-6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte-colony-stimulating factor (G-CSF)] from endothelial cells.

Oncostatin M (OSM), LIF, G-CSF, IL-6, and CNTF are structurally related members of the same cytokine family sharing similarities in their primary amino acid sequences, predicted secondary structure, and receptor components. OSM is a growth-regulating cytokine, affecting a number of tumor and normal cells. This material was first identified by its ability to inhibit the growth of A375 melanoma cells and other human tumor cells, but not inhibit the growth of normal human fibroblasts. It acts synergistically with TGF β1 to inhibit the proliferation of tumor cells like A375 melanoma cells. It induces an increase in LDL receptor expression and LDL uptake by hepatoma cells. OSM activates synovial fibroblast-like cells to produce urokinase type plasminogen activator. OSM is secreted by macrophages and activated T lymphocytes.

Lyophilized from a 0.2 μm filtered solution in 10 mM acetic acid, containing 50 μg of bovine serum albumin per 1 μg of cytokine.

The proliferative activity of human oncostatin M is tested in culture by using a human erythroleukemic cell line, TF-1.